Next Article in Journal
Efficacy and Safety of Xylitol Nasal Irrigation after Functional Endoscopic Sinus Surgery: A Randomized Controlled Study
Next Article in Special Issue
Epigenetic Characteristics in Primary and Recurrent Glioblastoma—Influence on the Clinical Course
Previous Article in Journal
Results of the Phase 1 Open-Label Safety Study of Umbilical Cord Lining Mesenchymal Stromal/Stem Cells (Corlicyte®) to Heal Chronic Diabetic Foot Ulcers
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies

by
Trang T. T. Nguyen
1,*,
Lloyd A. Greene
2,
Hayk Mnatsakanyan
3 and
Christian E. Badr
3
1
Ronald O. Perelman Department of Dermatology, Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, New York, NY 10016, USA
2
Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA
3
Department of Neurology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School, Boston, MA 02129, USA
*
Author to whom correspondence should be addressed.
Biomedicines 2024, 12(6), 1376; https://doi.org/10.3390/biomedicines12061376
Submission received: 9 May 2024 / Revised: 16 June 2024 / Accepted: 17 June 2024 / Published: 20 June 2024
(This article belongs to the Special Issue Glioblastoma: Pathogenetic, Diagnostic and Therapeutic Perspectives)

Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive forms of brain tumor, characterized by a daunting prognosis with a life expectancy hovering around 12–16 months. Despite a century of relentless research, only a select few drugs have received approval for brain tumor treatment, largely due to the formidable barrier posed by the blood–brain barrier. The current standard of care involves a multifaceted approach combining surgery, irradiation, and chemotherapy. However, recurrence often occurs within months despite these interventions. The formidable challenges of drug delivery to the brain and overcoming therapeutic resistance have become focal points in the treatment of brain tumors and are deemed essential to overcoming tumor recurrence. In recent years, a promising wave of advanced treatments has emerged, offering a glimpse of hope to overcome the limitations of existing therapies. This review aims to highlight cutting-edge technologies in the current and ongoing stages of development, providing patients with valuable insights to guide their choices in brain tumor treatment.
Keywords: glioblastoma multiforme; fMRI; temozolomide; TTFields; targeted therapy; external beam radiation therapy; gene and cell therapy; immunotherapy; artificial intelligence (AI) glioblastoma multiforme; fMRI; temozolomide; TTFields; targeted therapy; external beam radiation therapy; gene and cell therapy; immunotherapy; artificial intelligence (AI)

Share and Cite

MDPI and ACS Style

Nguyen, T.T.T.; Greene, L.A.; Mnatsakanyan, H.; Badr, C.E. Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies. Biomedicines 2024, 12, 1376. https://doi.org/10.3390/biomedicines12061376

AMA Style

Nguyen TTT, Greene LA, Mnatsakanyan H, Badr CE. Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies. Biomedicines. 2024; 12(6):1376. https://doi.org/10.3390/biomedicines12061376

Chicago/Turabian Style

Nguyen, Trang T. T., Lloyd A. Greene, Hayk Mnatsakanyan, and Christian E. Badr. 2024. "Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies" Biomedicines 12, no. 6: 1376. https://doi.org/10.3390/biomedicines12061376

APA Style

Nguyen, T. T. T., Greene, L. A., Mnatsakanyan, H., & Badr, C. E. (2024). Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies. Biomedicines, 12(6), 1376. https://doi.org/10.3390/biomedicines12061376

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop